A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DWP16001 Drug A and DWP16001 Drug C in Healthy Adult Volunteers
Latest Information Update: 06 Feb 2023
At a glance
- Drugs Enavogliflozin (Primary)
- Indications Metabolic disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 30 Jan 2023 Status changed from not yet recruiting to completed.
- 22 Jul 2022 New trial record